ArticleGynecologic oncology reports2025
Pembrolizumab and lenvatinib in the treatment of recurrent ovarian carcinoma: A single institution experience.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Advanced stage ovarian carcinoma has a poor prognosis with recurrence rates of over 80%, 5-year survival of 36-45%, and limited response to standard therapy. Pembrolizumab and lenvatinib are FDA approved for treatment of microsatellite stable (MSS)/mismatch repair proficient (pMMR) endometrial and renal cell cancers. Early phase II studies have shown promising results in a variety of advanced solid tumors, including ovarian cancer. We report on the clinical outcome of recurrent MSS/pMMR ovarian cancer patients treated with this therapy. Methods: For this retrospective cohort study, patients with a diagnosis of ovarian cancer treated with pembrolizumab and lenvatinib from January 2020 to April 2024 at MD Anderson Cancer Center at Cooper were identified. Demographic data, tumor characteristics, germline/somatic genetic testing, treatment duration, and toxicity were collected. Response rate by RECIST criteria, progression free survival (PFS), and clinical benefit rate were calculated. Results: Sixteen patients were identified. Most had high-grade serous (n = 11, 68.75 %) or clear cell histologies (n = 4, 25 %) and FIGO stage III/IV disease (n = 15, 93.75 %). Eighty-one percent had platinum resistant recurrent disease. Three patients discontinued therapy after one cycle, unrelated to drug toxicity, and were non-evaluable for response. Of 13 patients evaluable for response, 54 % had a partial response and 31 % had stable disease. The 6-month clinical benefit rate was 69 %. The median PFS for all evaluable patients was 7.9 months. At the time of data analysis, 2 patients remained on treatment. Conclusion: Pembrolizumab-lenvatinib therapy demonstrated favorable clinical benefit in recurrent, platinum resistant MSS/pMMR ovarian cancer, a group of patients in need of more therapeutic options.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.